Maxygen Company Profile (NASDAQ:MAXY)

About Maxygen (NASDAQ:MAXY)

Maxygen logoMaxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company's interests in Perseid Therapeutics LLC, the Company's former subsidiary, which included all of the Company's research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company's wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MAXY
  • CUSIP: 57777610
  • Web: N/A
  • Trailing P/E Ratio:
  • P/E Growth:
  • Dividend Yield: 1.0%
Frequently Asked Questions for Maxygen (NASDAQ:MAXY)

What is Maxygen's stock symbol?

Maxygen trades on the NASDAQ under the ticker symbol "MAXY."

Who are some of Maxygen's key competitors?

How do I buy Maxygen stock?

Shares of Maxygen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Maxygen's stock price today?

One share of Maxygen stock can currently be purchased for approximately $2.53.

MarketBeat Community Rating for Maxygen (NASDAQ MAXY)
Community Ranking:  1.4 out of 5 ()
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  5 (Vote Underperform)
Total Votes:  7
MarketBeat's community ratings are surveys of what our community members think about Maxygen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Maxygen (NASDAQ:MAXY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Maxygen (NASDAQ:MAXY)
No equities research coverage for this company has been tracked by


Earnings History for Maxygen (NASDAQ:MAXY)
Earnings by Quarter for Maxygen (NASDAQ:MAXY)
Earnings History by Quarter for Maxygen (NASDAQ MAXY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2013Q1 2013($0.08)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.06)ViewN/AView Earnings Details
11/6/2012Q312($0.08)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Maxygen (NASDAQ:MAXY)
Current Year EPS Consensus Estimate: $-0.11 EPS


Dividend History for Maxygen (NASDAQ:MAXY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Maxygen (NASDAQ:MAXY)
No insider trades for this company have been tracked by


Headline Trends for Maxygen (NASDAQ:MAXY)
Latest Headlines for Maxygen (NASDAQ:MAXY)
No headlines for this company have been tracked by



Maxygen (MAXY) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff